Dr. Edgar Diaz-Cruz had his manuscript titled “The CDK4/6 Inhibitor PD0332991 Reverses Epithelial Dysplasia Associated With Abnormal Activation of the Cyclin-CDK-Rb Pathway” in the journal Cancer Prevention Research.
Loss of normal growth control is a hallmark of cancer progression. An important strategy in cancer prevention treatment programs is to target the reversal of premalignant disease through re-differentiation. Utilizing a mouse model of dysplasia and an orally available CDK4/6 inhibitor (PD0332991) Diaz-Cruz and his team were able to identify cell cycle related proteins as mechanisms responsible for dysplasia persisting after an initial “genetic insult” was established. In particular, this study distinguished CDK4 and phosphorylated Rb as targets for cancer chemoprevention.
1900 Belmont Boulevard
Nashville, Tennessee 37212
About Belmont UniversityRanked No. 7 in the Regional Universities South category and named for the sixth consecutive year as one of the top “Up-and-Comer” universities by U.S. News & World Report, Belmont University consists of more than 6,900 students who come from every state and more than 25 countries. Committed to being a leader among teaching universities, Belmont brings together the best of liberal arts and professional education in a Christian community of learning and service. The University’s purpose is to help students explore their passions and develop their talents to meet the world’s needs, a fact made evident in the University’s hometown, Nashville, where students, faculty and staff served more than 243,000 hours of community service (valued at more than $5 million) during 2012. With more than 80 areas of undergraduate study, 22 master’s programs and five doctoral degrees, there is no limit to the ways Belmont University can expand an individual's horizon.
For more information visit www.belmont.edu